MARKET

PTN

PTN

Palatin Tech
AMEX
3.340
-0.130
-3.75%
After Hours: 3.390 +0.05 +1.50% 17:47 12/08 EST
OPEN
3.260
PREV CLOSE
3.470
HIGH
3.400
LOW
3.090
VOLUME
88.39K
TURNOVER
0
52 WEEK HIGH
16.00
52 WEEK LOW
3.090
MARKET CAP
34.58M
P/E (TTM)
-0.8559
1D
5D
1M
3M
1Y
5Y
Palatin Tech GAAP EPS of -$0.86 beats by $0.34, revenue of $0.87M beats by $0.08M
Seekingalpha · 11/14 12:34
Palatin Technologies Q1 EPS $(0.86) Beats $(1.19) Estimate, Sales $869.65K Beat $790.00K Estimate
Benzinga · 11/14 12:31
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quart...
PR Newswire · 11/14 12:30
Palatin Tech Q1 2023 Earnings Preview
Seekingalpha · 11/11 17:38
Notable earnings before Monday's open
Seekingalpha · 11/11 14:23
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10 13:55
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09 00:25
Palatin Technologies to Raise $10 Million Through Direct Offering of Common Stock, Warrants
Palatin Technologies to Raise $10 Million Through Direct Offering of Common Stock, Warrants
MT Newswires · 11/01 03:22
More
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCr) system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need. Its MCr system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. The Company’s commercial product Vyleesi (bremelanotide injection), is used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Company’s pipeline development programs include PL9643 MCr Agonist for dry eye disease and anti-inflammatory ocular indications, Oral PL8177 for inflammatory bowel diseases, and Melanocortin peptides for diabetic retinopathy. Its product development activities in inflammation disease indications focus on development of MCr peptides for ocular conditions, as well as conditions in the gut and kidney.

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.